A Study Of Imaging With Non-invasive Techniques In IBS

Overview

About this study

The purpose of this study is to evaluate the predictive ability of early trans abdominal ultrasound (TAUS) and trans perineal ultrasound (TPUS) for weeks 26 and 52 clinical and endoscopic outcomes in ulcerative colitis (UC) and Crohn’s disease (CD) patients starting targeted immune modulator (TIM) treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • (18+ years) with ulcerative colitis (UC) and Crohn’s disease (CD) initiating targeted immune modulator (TIM) therapy (biologics and oral small molecules).

  • Patients with UC and CD starting TIM within 2 weeks of a baseline endoscopy will be eligible.

Exclusion Criteria:

  • Concomitant enteric infection and prior colectomy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/18/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Manreet Kaur

Contact us for the latest status

Contact information:

Griffith Stratford

(480) 301-4251

Stratford.Griffith@mayo.edu

More information

Publications

Publications are currently not available